Super Micro Computer (SMCI) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.00%. A quarter ago, it was expected that this server technology company would post earnings of $0.44 per share when it actually produced earnings of $0.41, delivering a surprise of -6.82%.Over the last fou ...

Core Insights - Supernus Pharmaceuticals (SUPN) reported quarterly earnings of $1.01 per share, exceeding the Zacks Consensus Estimate of $0.82 per share, but down from $1.06 per share a year ago, resulting in an earnings surprise of +23.17% [1] - The company achieved revenues of $192.1 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.52% and showing an increase from $175.69 million year-over-year [2] - Supernus shares have increased approximately 54% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $208 million, while the estimate for the current fiscal year is $2.65 on revenues of $705.3 million [7] - The estimate revisions trend for Supernus was favorable prior to the earnings release, contributing to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Supernus belongs, is currently ranked in the top 18% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Amgen (AMGN) came out with quarterly earnings of $5.64 per share, beating the Zacks Consensus Estimate of $5 per share. This compares to earnings of $5.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.80%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $5.26 per share when it actually produced earnings of $6.02, delivering a surprise of +14.45%.Over the last four quarter ...

Core Insights - Exagen Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of -46.15% [1] - The company achieved revenues of $17.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.55% and showing a year-over-year increase from $12.51 million [2] - Exagen shares have increased approximately 188.5% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Exagen has surpassed consensus revenue estimates four times, but only exceeded EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $18.03 million, and for the current fiscal year, it is -$0.66 on revenues of $67.65 million [7] Industry Context - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Exagen's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Exagen's stock price movement will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for Exagen was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Core Insights - AC Immune reported a quarterly loss of $0.2 per share, which was better than the Zacks Consensus Estimate of a loss of $0.22, representing an earnings surprise of +9.09% [1] - The company posted revenues of $1.17 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 22.51%, and a significant decline from $29.45 million in the same quarter last year [2] - The stock has gained approximately 17.8% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of AC Immune's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $1.96 million, and for the current fiscal year, it is -$0.91 on revenues of $6.05 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Insights - Reservoir Media, Inc. reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.05 per share, compared to break-even earnings per share a year ago, resulting in an earnings surprise of -40.00% [1] - The company posted revenues of $45.44 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.32%, and showing an increase from year-ago revenues of $40.67 million [2] - Reservoir Media shares have declined approximately 18.5% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $42.03 million, and $0.12 on revenues of $166.74 million for the current fiscal year [7] Industry Context - The Media Conglomerates industry, to which Reservoir Media belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

分组1 - Integral Ad Science (IAS) reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, and down from $0.10 per share a year ago, representing an earnings surprise of -22.22% [1] - The company posted revenues of $154.36 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.32%, and up from $133.53 million year-over-year [2] - IAS has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed the market, losing about 2.1% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the coming quarter is $0.13 on revenues of $169.58 million, and for the current fiscal year, it is $0.35 on revenues of $602.2 million [7] - The Advertising and Marketing industry, to which IAS belongs, is currently in the bottom 42% of the Zacks industry rankings, which may impact stock performance [8]

分组1 - Neuronetics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, but an improvement from a loss of $0.29 per share a year ago, indicating an earnings surprise of -18.18% [1] - The company posted revenues of $37.3 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.21%, but showing significant growth from $18.53 million in the same quarter last year [2] - Neuronetics shares have increased approximately 72.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Neuronetics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $42.37 million, and for the current fiscal year, it is -$0.56 on revenues of $150.79 million [7] 分组3 - The Medical - Instruments industry, to which Neuronetics belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Verastem reported a quarterly loss of $1.35 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.51, marking an earnings surprise of -164.71% [1] - The company achieved revenues of $11.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 82.80%, compared to zero revenues a year ago [2] Financial Performance - The loss per share increased from $0.60 a year ago to $1.35 this quarter, indicating a worsening financial situation [1] - Over the last four quarters, Verastem has only surpassed consensus EPS estimates once [2] Stock Performance - Verastem shares have increased approximately 91.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $22.07 million, and for the current fiscal year, it is -$2.44 on revenues of $18.75 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is favorable, ranking in the top 39% of over 250 Zacks industries [8]

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.43%. A quarter ago, it was expected that this company would post earnings of $0.78 per share when it actually produced earnings of $0.68, delivering a surprise of -12.82%.Over the last four qu ...